Search Within

Carissa Laudati

Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
  3. Research Letter (1)
Groups
  1. Advanced Practice Providers (7)
  2. Nursing (7)
  3. Center for Hematologic Malignancies (5)
  4. Department of Medicine (5)
  5. Hematologic Malignancies, Division of (5)
  6. Adult Leukemia (4)

More Groups

People
  1. Lindsey Roeker (4)
  2. Meghan Thompson (4)
  3. Andrew Zelenetz (3)
  4. Anthony Mato (3)
  5. Gail Panton (3)
  6. Jae Park (3)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (2)
  4. 2018 (1)
  5. 2017 (1)
  6. 2011 (1)
Publications
  1. Blood (2)
  2. Clinical Cancer Research (1)
  3. Clinical Journal of Oncology Nursing (1)
  4. Leukemia (1)
  5. ONS Connect (1)
  6. Oncology Nursing Forum (1)
Publishers
  1. Oncology Nursing Society (ONS) (3)
  2. American Society of Hematology (2)
  3. American Association for Cancer Research (1)
  4. Nature Publishing Group (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
    Journal Article

    Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach
    Meeting Abstract

    Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
    Research Letter

    Roeker, L. E.; Knorr, D. A.; Thompson, M. C.; Nivar, M.; Lebowitz, S.; Peters, N.; Deonarine, I. Jr; Momotaj, S.; Sharan, S.; Chanlatte, V.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Hypersensitivity reactions: Priming practice change to reduce incidence in first-dose rituximab treatment
    Journal Article

    Laudati, C.; Clark, C.; Knezevic, A.; Zhang, Z.; Barton-Burke, M.
    Clinical Journal of Oncology Nursing (2018)

    Fulltext@MSK | Save
  • Implication of rituximab priming practices
    Meeting Abstract

    Laudati, C.; Clark, C.; Sumka, J.; Timoney, J.; Hamlin, P.
    Oncology Nursing Forum (2017)

    Fulltext@MSK | Save
  • Why did you switch from full-time to part-time?
    Journal Article

    Laudati, C.
    ONS Connect (2011)

    Fulltext@MSK | Save